10.12
人工多能性幹細胞
幹細胞とは、分裂してさまざまな種類の細胞を作り出す未分化な細胞です。通常、特定の種類の細胞に分化した細胞は、もはや分裂しない「ポスト有糸分裂」状態にあります。しかし、科学者たちは、これらの成熟した細胞を再プログラムする方法を発見しました。この方法では、細胞を脱分化させ、特殊化していない増殖可能な状態…
人工多能性幹細胞(iPSC)は、実験室で未分化胚性幹細胞に 近づけて設計された，皮膚細胞などの成熟した分化細胞です。すなわち，分裂，多能性で，体内であらゆる細胞型を産生することができます。例えば、網膜細胞は損傷した網膜組織を 置換するために使用できます。iPSCを作成するには、皮膚線維芽細胞のような成熟細胞を 患者から採取して培養します。次に，ふつうは，転写因子の遺伝子は ウイルスベクターによって細胞核に送達され、そこで遺伝子はゲノムに組み込まれます。転写因子は、胚性幹細胞によって 発現される遺伝子を 効果的に脱分化させ、それらを多能性状態にします。細胞は分裂できるようになり，培養中の特定の細胞型を産生するようにできるのが理想的である。その後、怪我または病気を治療するために、新しい細胞を患者に移植します。患者自身の細胞に由来するので、拒絶反応の危険性は最小限です。
View the full transcript and gain access to JoVE Core videos
Q1: What are induced pluripotent stem cells and how do they differ from other stem cells?
Induced pluripotent stem cells (iPSCs) are adult cells reprogrammed to an embryonic-like pluripotent state, capable of differentiating into any cell type. Unlike embryonic stem cells, iPSCs are generated from mature cells through genetic reprogramming, avoiding ethical concerns. This reprogramming involves activating master transcription regulators that reset gene expression patterns to enable unlimited self-renewal and differentiation potential.
Q2: How does gene expression control enable iPSC reprogramming?
iPSC reprogramming relies on precise gene expression control through transcription factors that activate pluripotency genes while silencing differentiation genes. Transcription regulators activators and repressors work together to rewrite the cellular epigenetic landscape. This coordinated regulation of expression occurs at multiple steps, from transcription initiation to translation, ensuring stable pluripotent identity and preventing spontaneous differentiation.
Q3: What role do transcription factors play in maintaining iPSC pluripotency?
Key transcription factors like Oct4, Sox2, and Nanog maintain iPSC pluripotency through combinatorial gene control synergistic action of transcription factors. These factors bind to regulatory DNA regions and recruit co-activators to activate pluripotency genes. Their cooperative binding of transcription regulators ensures robust, stable expression of genes required for self-renewal and prevention of differentiation.
Q4: How do eukaryotic transcription activators support iPSC function?
Eukaryotic transcription activators recruit co-activators and chromatin remodeling complexes to pluripotency gene promoters, facilitating RNA polymerase binding and transcription initiation. These activators recognize cis-regulatory sequences short fragments of non-coding DNA upstream of target genes. By assembling the pre-initiation complex at the eukaryotic promoter region, they enable robust expression of genes essential for iPSC maintenance.
Q5: What mechanisms prevent iPSCs from spontaneously differentiating?
iPSCs maintain pluripotency through active repression of differentiation genes via eukaryotic transcription inhibitors inhibiting DNA binding and blocking access to differentiation-promoting genes. Repressor proteins and silencing complexes bind regulatory regions to suppress lineage-specific gene expression. This dual mechanism of activating pluripotency genes while repressing differentiation genes creates a stable pluripotent state resistant to spontaneous differentiation.
Q6: How can iPSCs be directed to differentiate into specific cell types?
iPSC differentiation is controlled by removing pluripotency-maintaining signals and introducing lineage-specific transcription factors that activate cell-type-specific genes. This process involves coordinated changes in gene expression during transcription and translation stages. By manipulating transcriptional regulation through growth factors and signaling molecules, researchers can guide iPSCs toward desired cell fates for regenerative medicine applications.
Q7: What are the therapeutic applications of iPSC technology?
iPSCs enable generation of patient-specific cells for disease modeling, drug testing, and cell replacement therapies without immune rejection. Their ability to differentiate into any cell type makes them valuable for treating degenerative diseases, injuries, and genetic disorders. iPSC-derived cells bypass ethical concerns associated with embryonic stem cells while offering personalized regenerative medicine approaches for previously untreatable conditions.